glp 1 agonist osteoporosis GLP-1 Drugs May Raise the Risk of and Gout, Study Suggests The Beneficial Effects of GLP-1

Losing it creates a physiological paradox: the patient achieves a lower body weight but may simultaneously compromise the metabolic machinery that is needed to maintain it

Bagnoli F, Buti L, Tompkins L et al (2005) Helicobacter pylori CagA induces a transition from polarized to invasive phenotypes in MDCK cells

Stone, W

The favorable results from the placebo-controlled FLOW trial, conducted with semaglutide 1.0 mg in patients with T2D and chronic kidney disesase (CKD), are about to be disclosed, while ongoing dedicated trials will further explore the effects of OW semaglutide 2.4 mg (NCT04889183) and tirzepatide (NCT05536804) on kidney function parameters in obese/overweight individuals at high risk of CKD progression regardless of T2D